C Holmes

Summary

Affiliation: University of Southampton
Country: UK

Publications

  1. ncbi Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy
    Elina Zotova
    Division of Clinical Neurosciences, School of Medicine, University of Southampton, Mailpoint 806, Level D, South Pathology Block, Southampton General Hospital, Southampton, SO16 6YD, UK
    Alzheimers Res Ther 2:1. 2010
  2. ncbi Genetic variation in the 5-HT2A receptor and altered neocortical [3H] ketanserin binding in Alzheimer's disease
    C Holmes
    University of Southampton, Clinical Neurosciences Research Division, Memory Assessment and Research Centre, Moorgreen Hospital, Botley Rd, Southampton, United Kingdom
    Neurosci Lett 420:58-60. 2007
  3. ncbi Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation
    C Holmes
    University of Southampton, Clinical Neurosciences Research Division, Memory Assessment and Research Centre, Moorgreen Hospital, Botley Road, Southampton, UK
    J Neurol Neurosurg Psychiatry 76:640-3. 2005
  4. ncbi The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease
    C Holmes
    Memory Assessment and Research Centre, University of Southampton, Clinical Neurosciences Research Division, Moorgreen Hospital, Botley Rd, Southampton, UK
    Neurology 63:214-9. 2004
  5. ncbi Proinflammatory cytokines, sickness behavior, and Alzheimer disease
    C Holmes
    University of Southampton, Memory Assessment and Research Centre, Botley Rd, Southampton, UK, SO30 3JB
    Neurology 77:212-8. 2011
  6. ncbi A randomised placebo controlled study to assess the effects of cholinergic treatment on muscarinic receptors in Alzheimer's disease
    P M Kemp
    Department of Nuclear Medicine, Southampton University Hospitals Trust, Southampton, UK
    J Neurol Neurosurg Psychiatry 74:1567-70. 2003
  7. ncbi Systemic inflammation and disease progression in Alzheimer disease
    C Holmes
    Clinical Neurosciences Division, University of Southampton, UK
    Neurology 73:768-74. 2009
  8. ncbi Microglial alterations in human Alzheimer's disease following Aβ42 immunization
    E Zotova
    Division of Clinical Neurosciences, School of Medicine, University of Southampton, UK
    Neuropathol Appl Neurobiol 37:513-24. 2011
  9. ncbi Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain
    D Boche
    Division of Clinical Neurosciences, University of Southampton, Southampton General Hospital, Southampton, UK
    Brain 131:3299-310. 2008
  10. ncbi Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease
    C Holmes
    School of Medicine and Biological Sciences, University of Southampton, Southampton, UK
    J Neurol Neurosurg Psychiatry 74:788-9. 2003

Collaborators

Detail Information

Publications14

  1. ncbi Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy
    Elina Zotova
    Division of Clinical Neurosciences, School of Medicine, University of Southampton, Mailpoint 806, Level D, South Pathology Block, Southampton General Hospital, Southampton, SO16 6YD, UK
    Alzheimers Res Ther 2:1. 2010
    ....
  2. ncbi Genetic variation in the 5-HT2A receptor and altered neocortical [3H] ketanserin binding in Alzheimer's disease
    C Holmes
    University of Southampton, Clinical Neurosciences Research Division, Memory Assessment and Research Centre, Moorgreen Hospital, Botley Rd, Southampton, United Kingdom
    Neurosci Lett 420:58-60. 2007
    ....
  3. ncbi Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation
    C Holmes
    University of Southampton, Clinical Neurosciences Research Division, Memory Assessment and Research Centre, Moorgreen Hospital, Botley Road, Southampton, UK
    J Neurol Neurosurg Psychiatry 76:640-3. 2005
    ..To determine whether individuals with Alzheimer's disease (AD) and the K variant allele of butyrylcholinesterase have a slower rate of cognitive decline than those without the K variant allele of butyrylcholinesterase...
  4. ncbi The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease
    C Holmes
    Memory Assessment and Research Centre, University of Southampton, Clinical Neurosciences Research Division, Moorgreen Hospital, Botley Rd, Southampton, UK
    Neurology 63:214-9. 2004
    ..To determine the efficacy of donepezil in the treatment of neuropsychiatric symptoms in patients with Alzheimer disease (AD) in a randomized withdrawal study...
  5. ncbi Proinflammatory cytokines, sickness behavior, and Alzheimer disease
    C Holmes
    University of Southampton, Memory Assessment and Research Centre, Botley Rd, Southampton, UK, SO30 3JB
    Neurology 77:212-8. 2011
    ....
  6. ncbi A randomised placebo controlled study to assess the effects of cholinergic treatment on muscarinic receptors in Alzheimer's disease
    P M Kemp
    Department of Nuclear Medicine, Southampton University Hospitals Trust, Southampton, UK
    J Neurol Neurosurg Psychiatry 74:1567-70. 2003
    ..To determine the effects of cholinergic treatment on the muscarinic receptor in patients with Alzheimer's disease...
  7. ncbi Systemic inflammation and disease progression in Alzheimer disease
    C Holmes
    Clinical Neurosciences Division, University of Southampton, UK
    Neurology 73:768-74. 2009
    ..Previous preclinical research shows that acute systemic inflammation contributes to an exacerbation of neurodegeneration by activation of primed microglial cells...
  8. ncbi Microglial alterations in human Alzheimer's disease following Aβ42 immunization
    E Zotova
    Division of Clinical Neurosciences, School of Medicine, University of Southampton, UK
    Neuropathol Appl Neurobiol 37:513-24. 2011
    ..We have investigated the effects of Aβ42 immunization on microglial activation and the relationship with Aβ42 load in human AD...
  9. ncbi Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain
    D Boche
    Division of Clinical Neurosciences, University of Southampton, Southampton General Hospital, Southampton, UK
    Brain 131:3299-310. 2008
    ..The extent to which these vascular alterations following Abeta immunization in Alzheimer's disease are reflected in changes in cognitive function remains to be determined...
  10. ncbi Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease
    C Holmes
    School of Medicine and Biological Sciences, University of Southampton, Southampton, UK
    J Neurol Neurosurg Psychiatry 74:788-9. 2003
    ..Further research is needed to determine whether recurrent systemic infections drive cognitive decline in Alzheimer's disease subjects through a cytokine mediated pathway...
  11. ncbi Alzheimer's disease: differences in technetium-99m HMPAO SPECT scan findings between early onset and late onset dementia
    P M Kemp
    Department of Nuclear Medicine, Southampton University Hospitals Trust, Southampton, UK
    J Neurol Neurosurg Psychiatry 74:715-9. 2003
    ..To compare the HMPAO SPECT cerebral perfusion patterns in early and late onset Alzheimer's disease...
  12. ncbi Psychosis and aggression in Alzheimer's disease: the effect of dopamine receptor gene variation
    C Holmes
    University of Southampton, Community Clinical Sciences Research Division, Memory Assessment and Research Centre, Moorgreen Hospital, Botley Road, West End, Southampton SO30 3JB, UK
    J Neurol Neurosurg Psychiatry 71:777-9. 2001
    ..Specifically, carriers of the DRD1 B2 allele were more likely to be aggressive or experience hallucinations whereas homozygous carriers of the DRD3 1 allele were more likely to experience delusions...
  13. ncbi Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease
    P G Kehoe
    Nat Genet 21:71-2. 1999
  14. ncbi Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation
    D S Goldstein
    Clinical Neurocardiology Section, National Institutes on Neurological Disorders and Stroke, National Institute on Aging, NIH, Bethesda, MD 20892 1620, USA
    Neurology 69:1580-4. 2007
    ..Familial PD caused by mutation of the gene encoding alpha-synuclein or by alpha-synuclein gene triplication also features cardiac sympathetic denervation and baroreflex failure...